B. Riley Securities Reiterates Buy Rating on Ascentage Pharma

B. Riley Securities maintains its buy rating on Ascentage Pharma with a $45 price target.

Written by Trueearnings · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 15, 2026, 3:00 AM EDT

Key Points

B. Riley Securities reiterated its buy rating for Ascentage Pharma Group Internat (AAPG) with a $45 target on June 10, 2026.
Ascentage shares traded at $17.60, with a market cap of about $1.64 billion, and a 52-week high of $48.45.
Analysts have set a consensus target price of $47.56, and the stock is recommended as a strong buy.

B. Riley Securities reiterated its buy rating on Ascentage Pharma Group Internat (NasdaqGM: AAPG) on June 10, 2026. Analyst Mayank Mamtani set a price target of $45 for the stock.

Analysts Set New Price Targets

On June 10, 2026, B. Riley Securities reiterated its buy rating on Ascentage Pharma Group Internat with a $45 price target. Other analysts have also shown optimism. BTIG assumed coverage with a buy rating and a $48 target on March 12, 2026. Oppenheimer initiated a buy rating with a $45 target on December 4, 2025, while Truist Securities and BTIG both started coverage with buy ratings and targets of $51 and $50, respectively, in late 2025.

Ascentage Pharma Stock Snapshot

Shares of Ascentage Pharma Group Internat (NasdaqGM: AAPG) were trading around $17.60. The company has a market cap of approximately $1.64 billion. Despite a negative forward P/E ratio, indicating the company isn't currently profitable, Ascentage has a beta of 0.652, suggesting less volatility compared to the market. The stock's 52-week range spans from $16.92 to $48.45, with moving averages of $22.00 over 50 days and $28.33 over 200 days. The company maintains a current ratio of 1.792 and a quick ratio of 1.688, though it carries a high debt-to-equity ratio of 148.381.

Recent Earnings

Ascentage Pharma reported revenues of $574.12 million, with a modest revenue growth of 1.17%. However, the company is currently not profitable, with a net margin of -216.47% and a return on equity of -154.56%. The next earnings report is expected on March 25, 2026.

About Ascentage Pharma Group Internat

Ascentage Pharma Group International is a biotechnology company based in Suzhou, China. It focuses on developing therapies for cancer, chronic hepatitis B, and age-related diseases. Key products include HQP1351, a BCR-ABL inhibitor, and APG-2575, a Bcl-2 selective inhibitor. With 767 employees, the company is led by CEO Dr. Dajun Yang and collaborates with various research institutions and pharmaceutical companies.

Bottom Line

B. Riley Securities' reaffirmation of its buy rating on Ascentage Pharma underscores confidence in the company's potential, despite current profitability challenges. Investors often track analyst ratings as they can influence stock performance, though it's important to remember that these ratings are based on past data and expectations. Ascentage's development pipeline and strategic partnerships remain key factors for its growth prospects.